Methyltestosterone

  • Circulating lipid and lipoprotein concentrations with oral estrogen-androgen hormone replacement therapy
    David D. Youngs, MD, Byron J. Hoogwerf, MD, Leslie R. Schover, PhD and Ruth K. Cannata, RN
    Cleveland Clinic Journal of Medicine July 1992, 59 (4) 357-358;

    A decrease in high-density lipoprotein cholesterol was observed in a group of postmenopausal women following oral estrogen-androgen therapy, suggesting that the potential benefits—sexual and psychological well-being— should be weighed against the potential cardiovascular risks associated with adverse lipid changes.